NWI Management’s Cogent Biosciences COGT Stock Holding History

NWI Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.35M	Hold	241,671	–	–	0.43%	36
2026 Q1	$9.3M	Hold	241,671	–	–	0.53%	34
2025 Q4	$8.58M	Buy	+241,671	New	+$6.79M	0.4%	39

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NWI Management's COGT Position: Q2 2026 in Review

NWI Management held its Cogent Biosciences (COGT) position steady in Q2 2026 at 241,671 shares worth $9.35M. The position accounts for 0.43% of the portfolio, ranked #36.

NWI Management first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

NWI Management held 241,671 shares of Cogent Biosciences worth $9.35M as of Q2 2026.
NWI Management left its Cogent Biosciences share count unchanged in Q2 2026.
Cogent Biosciences made up 0.43% of NWI Management's portfolio in Q2 2026, its #36 holding.
NWI Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on NWI Management's 13F filing for Q2 2026, filed 14 Aug 2026.